Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 862

1.

Liver transplantation for hepatocellular carcinoma under calcineurin inhibitors: reassessment of risk factors for tumor recurrence.

Vivarelli M, Cucchetti A, La Barba G, Ravaioli M, Del Gaudio M, Lauro A, Grazi GL, Pinna AD.

Ann Surg. 2008 Nov;248(5):857-62. doi: 10.1097/SLA.0b013e3181896278.

PMID:
18948815
2.

Analysis of risk factors for tumor recurrence after liver transplantation for hepatocellular carcinoma: key role of immunosuppression.

Vivarelli M, Cucchetti A, Piscaglia F, La Barba G, Bolondi L, Cavallari A, Pinna AD.

Liver Transpl. 2005 May;11(5):497-503.

3.

Effect of different immunosuppressive schedules on recurrence-free survival after liver transplantation for hepatocellular carcinoma.

Vivarelli M, Dazzi A, Zanello M, Cucchetti A, Cescon M, Ravaioli M, Del Gaudio M, Lauro A, Grazi GL, Pinna AD.

Transplantation. 2010 Jan 27;89(2):227-31. doi: 10.1097/TP.0b013e3181c3c540.

PMID:
20098287
4.

Reduced exposure to calcineurin inhibitors early after liver transplantation prevents recurrence of hepatocellular carcinoma.

Rodríguez-Perálvarez M, Tsochatzis E, Naveas MC, Pieri G, García-Caparrós C, O'Beirne J, Poyato-González A, Ferrín-Sánchez G, Montero-Álvarez JL, Patch D, Thorburn D, Briceño J, De la Mata M, Burroughs AK.

J Hepatol. 2013 Dec;59(6):1193-9. doi: 10.1016/j.jhep.2013.07.012. Epub 2013 Jul 16.

PMID:
23867318
5.
6.

Rate of tumor growth predicts recurrence of hepatocellular carcinoma after liver transplantation in patients beyond Milan or UCSF criteria.

Hanouneh IA, Macaron C, Lopez R, Aucejo F, Zein NN.

Transplant Proc. 2011 Dec;43(10):3813-8. doi: 10.1016/j.transproceed.2011.09.043.

PMID:
22172852
7.

Liver transplantation for hepatocellular carcinoma: Hangzhou experiences.

Zheng SS, Xu X, Wu J, Chen J, Wang WL, Zhang M, Liang TB, Wu LM.

Transplantation. 2008 Jun 27;85(12):1726-32. doi: 10.1097/TP.0b013e31816b67e4.

PMID:
18580463
8.

HCC in living donor liver transplantation: can we expand the Milan criteria?

Kwon CH, Kim DJ, Han YS, Park JB, Choi GS, Kim SJ, Joh JW, Lee SK.

Dig Dis. 2007;25(4):313-9.

PMID:
17960066
9.

Indications and management of everolimus after liver transplantation.

Bilbao I, Sapisochin G, Dopazo C, Lazaro JL, Pou L, Castells L, Caralt M, Blanco L, Gantxegi A, Margarit C, Charco R.

Transplant Proc. 2009 Jul-Aug;41(6):2172-6. doi: 10.1016/j.transproceed.2009.06.087.

PMID:
19715864
10.

Liver transplantation and recurrent hepatocellular carcinoma: predictive value of nodule size in a retrospective and explant study.

Grasso A, Stigliano R, Morisco F, Martines H, Quaglia A, Dhillon AP, Patch D, Davidson BR, Rolles K, Burroughs AK.

Transplantation. 2006 Jun 15;81(11):1532-41.

PMID:
16770242
11.

Immunosuppression affects the rate of recurrent primary biliary cirrhosis after liver transplantation.

Neuberger J, Gunson B, Hubscher S, Nightingale P.

Liver Transpl. 2004 Apr;10(4):488-91.

12.

[Risk factors for early recurrence after surgical resection for hepatocellular carcinoma].

Park UJ, Kim YH, Kang KJ, Lim TJ.

Korean J Hepatol. 2008 Sep;14(3):371-80. doi: 10.3350/kjhep.2008.14.3.371. Korean.

PMID:
18815460
13.

Recurrent hepatocellular carcinoma after transplantation: use of a pathological score on explanted livers to predict recurrence.

Parfitt JR, Marotta P, Alghamdi M, Wall W, Khakhar A, Suskin NG, Quan D, McAllister V, Ghent C, Levstik M, McLean C, Chakrabarti S, Garcia B, Driman DK.

Liver Transpl. 2007 Apr;13(4):543-51.

14.

CD147, MMP-2, MMP-9 and MVD-CD34 are significant predictors of recurrence after liver transplantation in hepatocellular carcinoma patients.

Zhang Q, Chen X, Zhou J, Zhang L, Zhao Q, Chen G, Xu J, Qian F, Chen Z.

Cancer Biol Ther. 2006 Jul;5(7):808-14. Epub 2006 Jul 30.

PMID:
16775432
15.

Low recurrence rate of hepatocellular carcinoma after liver transplantation: better patient selection or lower immunosuppression?

Vivarelli M, Bellusci R, Cucchetti A, Cavrini G, De Ruvo N, Aden AA, La Barba G, Brillanti S, Cavallari A.

Transplantation. 2002 Dec 27;74(12):1746-51.

PMID:
12499891
16.

Risk factors of the recurrence of hepatocellular carcinoma originating from residual cancer cells after hepatectomy.

Shimada M, Hasegawa H, Gion T, Shirabe K, Taguchi K, Takenaka K, Tanaka S, Sugimachi K.

Hepatogastroenterology. 1999 Jul-Aug;46(28):2469-75.

PMID:
10522022
17.

Morphological features of advanced hepatocellular carcinoma as a predictor of downstaging and liver transplantation: an intention-to-treat analysis.

Barakat O, Wood RP, Ozaki CF, Ankoma-Sey V, Galati J, Skolkin M, Toombs B, Round M, Moore W, Mieles L.

Liver Transpl. 2010 Mar;16(3):289-99. doi: 10.1002/lt.21994.

19.

[Prognostic factors of hepatocellular carcinoma after liver transplantation].

Zhou LX, Yan LN.

Ai Zheng. 2006 Jun;25(6):736-9. Chinese.

PMID:
16764771
20.

Sirolimus-based immunosuppression therapy in liver transplantation for patients with hepatocellular carcinoma exceeding the Milan criteria.

Zhou J, Wang Z, Wu ZQ, Qiu SJ, Yu Y, Huang XW, Tang ZY, Fan J.

Transplant Proc. 2008 Dec;40(10):3548-53. doi: 10.1016/j.transproceed.2008.03.165.

PMID:
19100435

Supplemental Content

Support Center